Cargando…
Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer
About half of the patients treated with docetaxel in the setting of metastatic castration-resistant prostate cancer (CRPC) are non-responders. Therefore, a marker of response would be beneficial for clinical decision-making. We evaluated class III β-tubulin (βIII-tubulin) expression as a predictor o...
Autores principales: | Maahs, Lucas, Sanchez, Bertha E., Gupta, Nilesh, Van Harn, Meredith, Barrack, Evelyn R., Reddy, Prem-veer, Hwang, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816559/ https://www.ncbi.nlm.nih.gov/pubmed/31658275 http://dx.doi.org/10.1371/journal.pone.0222510 |
Ejemplares similares
-
Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death
por: Reddy, Vidyavathi, et al.
Publicado: (2019) -
Increased expression of class III β-tubulin in castration-resistant human prostate cancer
por: Terry, S, et al.
Publicado: (2009) -
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015) -
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011) -
Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)